Nutra Pharma Corp.
Bringing Healthcare Solutions to the World
Recent News
Press Kit
Drug Development
R&D Pipeline
Nutra Pharma is developing an innovative pipeline of biopharmaceutical products
Signup to receive news and announcements from Nutra Pharma:
First Name:
Last Name:
Infinite Menus, Copyright 2006, OpenCube Inc. All Rights Reserved.


Ohio State University Researcher Receives Competitive Grant Utilizing Infectech, Inc. Technology
August 30, 2004

Nutra Pharma Corp., a biotechnology holding company that owns rights to patents and intellectual property related to the development of drugs for HIV and Multiple Sclerosis has announced today that its majority owned subsidiary, Infectech, Inc. (Pink Sheets:IFEC - News), received a matching funds grant through a research proposal at Ohio State University.

Dr. Srinand Sreevatsan of the Food Animal Health Research Program of Ohio State University was chosen by the OARDC (Ohio Agricultural Research and Development Center) competitive grants program for the funding of his proposal entitled Assessment of the use of Paraffin Baiting for Diagnostic of the Johne's Disease Pathogen, Mycobacterium avium subspecies paratuberculosis (MAP). Infectech, Inc. owns the patents, which Dr. Sreevatsan is utilizing for his approved grant. Mycobacteria are responsible worldwide for billions of dollars in damage annually to the cattle industry. Specifically, Mycobacterium avium is a leading cause of disease in AIDS patients worldwide. The Infectech technology will allow for a more rapid and efficient detection and treatment of this pathogen.

"This grant will allow for some important validation of Infectech's patented technology," commented Dr. Mitchell Felder, Chief Executive Officer for Infectech. "Third-party validation in commercially-viable applications should rapidly move our technology through the FDA approval process and into the marketplace."

Infectech owns 29 issued patents related to the rapid isolation, growth, identification and antibiotic sensitivity of disease causing bacteria such as Tuberculosis ("TB") and Mycobacterium avium-intracellulare ("MAI"). Infectech's researchers discovered that certain grades of paraffin wax, when used in conjunction with a microscope slide, and combined with a nutrient broth, provides for the rapid isolation, growth and identification of various disease causing bacteria. Infectech has developed a diagnostic test kit based on this technology. The basic test kit consists of a glass slide coated with paraffin, which is used as a carbon (food) source by certain pathogenic bacterial species such as TB. The slides are incubated in a sample of almost any bodily fluid (a non-invasive sample of saliva is preferred) within a nutrient broth. This creates a semi-solid growth medium for the bacteria, which imitates its natural environment within a human or animal host. The bacteria collect on the paraffin slide in 4-8 days. Testing can then be done to identify the species of bacteria. This testing can be done via acid-fast staining or through PCR gene amplification. Additionally, the bacteria can be cultured with antibiotics to test for specific sensitivities. Through the choice of different nutrient broths, each kit can be tailored to encourage the growth of a specific bacterium. The test kits are being designed to work on a class of bacteria that includes TB, MAI, Para-tuberculosis, Pseudomonas and Nocardia.

"We are very excited about the opportunity to have researchers from Ohio State University work with this technology," said Rik Deitsch, Nutra Pharma's Chief Executive Officer. "They have a proven track record in microbiology research that will go a long way in helping Infectech gain regulatory approval, bringing the Company to revenues in the near future," he added.

SEC Disclaimer

This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). The matching funds grant at Ohio State University should not be construed as an indication in any way whatsoever of the value of the Company or its common stock. The Company's filings may be accessed at the SEC's Edgar system at Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

Quick Nav
Nyloxin // Chronic Pain Relief
Read about Jeff Gottfurcht, the first rheumatoid arthritis sufferer to conquer Everest, in Musculoskeletal Health a special section of the Washington Post.


Recent News
August 03, 2017
New Edition of Textbook on Treating Canine Arthritis Includes Nutra Pharma Pain Remedy

June 21, 2017
Nutra Pharma Announcing Launch of Luxury Feet

June 07, 2017
Nutra Pharma Featured on Univision's Spanish-Language News Show: Primer Impacto

Click here to view a Letter to Shareholders from the Company's CEO, Rik J Deitsch.
Facebook   Twitter
Privacy Policy Code of Ethics